MetaVia - Public Comps and Valuation Multiples

MetaVia Overview

About MetaVia

MetaVia Inc is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases. It has two programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and obesity. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and Type 2 Diabetes Mellitus (T2DM). DA-1726 is a novel oxyntomodulin (OXM) analogue functioning as a GLP-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist for the treatment of obesity that is designed to be administered once weekly subcutaneously.

Founded

2014

HQ

Employees

Website

metaviatx.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$44K

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

MetaVia Financials

MetaVia has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, MetaVia achieved revenue of n/a and an EBITDA of -$28.8M.

MetaVia expects next 12-month revenue of XXX and NTM EBITDA of XXX

See MetaVia valuation multiples based on analyst estimates

MetaVia P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$12.5M	-$28.8M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	-$14.0M	-$12.5M	XXX	XXX	XXX
Net Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

MetaVia Stock Performance

As of April 15, 2025, MetaVia's stock price is $2.

MetaVia has current market cap of $15.9M, and EV of $44K.

See MetaVia trading valuation data

MetaVia Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$44K	$15.9M	XXX	XXX	XXX	XXX	$-2.95

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

MetaVia Valuation Multiples

As of April 15, 2025, MetaVia has market cap of $15.9M and EV of $44K.

MetaVia's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate MetaVia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for MetaVia and 10K+ public comps

MetaVia Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$44K	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-0.0x	XXX	XXX	XXX
P/E	-0.6x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-0.0x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get MetaVia Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

MetaVia Valuation Multiples

MetaVia's NTM/LTM revenue growth is n/a

MetaVia's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $3.2M for the same period.

Over next 12 months, MetaVia's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate MetaVia's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for MetaVia and other 10K+ public comps

MetaVia Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	131%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$3.2M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry